ASH 2017 Annual Meeting Highlights in Hodgkin Lymphoma

Early Interim PET in Patients with Advanced-Stage HL Treated within the Phase 3 GHSG HD18 Study Peter Borchmann, MD Begin

Phase II Study of Brentuximab Vedotin Plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma Robert W. Chen, MD Begin

Phase 2 Checkmate 205 Study Looking at Nivolumab for Newly Diagnosed Advanced-Stage cHL and Outcomes in Patients with Relapsed/Refractory cHL Jonathon B. Cohen, MD, MS Begin

Positive Phase 3 Data from ECHELON 1 Clinical Trial Comparing A+AVD as Frontline Therapy in Previously Untreated Advanced HL Joseph M. Connors, MD, FRCPC Begin

Studies That Will Impact or Shape Treatment of HL in 2018 Matthew Matasar, MD Begin